文献速递神经肿瘤

胶质母细胞瘤基因表达与甲基化调控的生物信息学分析

Bioinformatic analysis of gene expression and methylation regulation in glioblastoma.
PubMed 文献 · J Neurooncol · 2017-11-22

该研究利用癌症基因组图谱(TCGA)RNA测序(676例)和DNA甲基化(Illumina Human Methylation 450K;657例)数据库筛查受DNA甲基化影响的差异表达基因,并在中国脑胶质瘤基因组图谱(CGGA)RNA测序数据库和TCGA DNA甲基化(Illumina Human Methylation 27K;283例)中验证。共鉴定3365个差异表达基因,其中2940个低甲基化高表达、425个高甲基化低表达;建立8基因特征以切点27.24将患者分为两组,高风险组中位总生存期较短(15.77 vs 10.61个月;P=0.0002)。

要点

  • 共鉴定3365个差异表达基因,2940个低甲基化高表达,425个高甲基化低表达。
  • 8基因特征以切点27.24将GBM患者分为两组,高风险组中位OS较短(15.77 vs 10.61个月;P=0.0002)。
  • 8基因特征对GBM患者具有独立预后价值,并可在额外数据集中验证。

核心结论

  • 检测到受DNA甲基化修饰影响的差异表达基因,8基因特征对GBM患者具有独立预后价值。

研究设计与样本

  • 纳入TCGA RNA测序(676例)和DNA甲基化(Illumina Human Methylation 450K;657例)数据库检测基因表达与甲基化谱。
  • 纳入CGGA RNA测序数据库和TCGA DNA甲基化(Illumina Human Methylation 27K;283例)进行验证。
  • 使用主成分分析(PCA)识别基因表达与DNA甲基化状态。

主要发现

  • 共鉴定3365个差异表达基因,其中2940个基因在GBM中低甲基化高表达,425个基因高甲基化低表达。
  • 建立8基因(C9orf64、OSMR、MDK、MARVELD1、PTRF、MYD88、BIRC3、RPP25)特征,以切点27.24将GBM患者分为两组。
  • 高风险组中位总生存期较低风险组短(15.77 vs 10.61个月;P=0.0002)。
  • 两组间呈现不同的临床和分子特征。
  • 上述发现可在额外数据集中验证。

关键数值与推荐

  • 8基因特征切点为27.24。
  • 高风险组 vs 低风险组中位OS:15.77 vs 10.61个月;P=0.0002。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Different gene expression and methylation profiles are identified in glioblastoma (GBM). To screen the differentially expressed genes affected by DNA methylation modification and further investigate their prognostic values for GBMs. We included The Cancer Genome Atlas (TCGA) RNA sequencing (676) and DNA methylation (Illumina Human Methylation 450K; 657) databases to detect the gene expression and methylation profiles. Chinese Glioma Genome Atlas (CGGA) RNA sequencing database and TCGA DNA methylation (Illumina Human Methylation 27K; 283) was included for validation. Gene expression and DNA methylation statues were identified using principal components analysis (PCA). A total of 3365 differentially expressed genes were identified. Among them, 2940 genes showed low methylation and high expression, while 425 genes showed high methylation and low expression in GBMs. An eight-gene (C9orf64, OSMR, MDK, MARVELD1, PTRF, MYD88, BIRC3, RPP25) signature was established to divide GBM patients into two groups based on the cut-off point (27.24). The high risk group had shorter overall survival (OS) than low risk group (median OS 15.77 vs. 10.61 months; P = 0.0002). Moreover, the different clinical and molecular features were shown between two groups. These findings could be validated in additional datasets. The differentially expressed genes affected by DNA methylation modification were detected. Our results showed that the eight-gene signature has independently prognostic value for GBM patients.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Wang W, Zhao Z, Wu F, et al. Bioinformatic analysis of gene expression and methylation regulation in glioblastoma. J Neurooncol. 2017. PMID: 29168084. doi:10.1007/s11060-017-2688-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。